Following an abandoned collaboration agreement between a complex peptide formulator and a generic manufacturer, CRA was retained to support an academic senior consultant in the ensuing arbitration. CRA’s team examined lost profit damages for the formulator, examining uptake and pricing of the specialty drug with an orphan drug indication. The matter ultimately settled.
2023 International Arbitration review: Updates and trends
2023 marked a significant surge in activity across diverse sectors such as mining, oil & gas, the energy transition, pharma, and merger disputes. Throughout...